Skip to content
  1. Home
  2. Latest news
  3. Innovation
  4. Meet 3 men who’ve been on the front lines of HIV treatments for decades
Left to right: Joss J. De Wet, M.D., Johnson & Johnson's Brian Woodfall, M.D., and artist Tiko Kerr
Left to right: Joss J. De Wet, M.D., Johnson & Johnson’s Brian Woodfall, M.D., and artist Tiko Kerr Andy Meyers at M3 Creative

Meet 3 men who’ve been on the front lines of HIV treatments for decades

Johnson & Johnson’s Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That’s where he met Tiko Kerr, who became one of the first patients to take the company’s HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.

Left to right: Joss J. De Wet, M.D., Johnson & Johnson’s Brian Woodfall, M.D., and artist Tiko Kerr Andy Meyers at M3 Creative
hqdefault.jpg

We’re committed to helping lead the fight against HIV/AIDS

Read about the many ways Johnson & Johnson is working to #makeHIVhistory.

More from Johnson & Johnson

Terra Kremer, Ph.D., is on a mission to create self-sterilizing surgical tools

Since its launch, Johnson & Johnson has focused on helping make surgeries safer. Learn how this analytical microbiologist and her team are continuing in that tradition with a digital app that aims to change the way medical devices are designed and sterilized.

What is lupus?

Up to 5 million people worldwide live with this complex autoimmune condition, which is more prevalent in women and has a greater disease severity in Latin Americans and patients of African ancestry. Learn how Johnson & Johnson is working to innovate treatments for autoimmune diseases.

This scientist develops targeted treatments for cancer—here’s what drives and inspires him

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.